1. In Vivo
  2. >>Manufacturing Focus

Lilly & Boehringer: When You Gotta Partner, You Gotta Partner

Lilly's co-promotion with Boehringer Ingelheim of duloxetine is the first time the American company has signed a major marketing deal for one of its own products. The company notes the collaboration is part of its broad commitment to partnering and that the market is intensely competitive. But the choice of duloxetine--the launch of which may be delayed indefinitely because of manufacturing problems--also represents Lilly's lowest-risk option for subsidizing the launches, and maximizing the returns from, potentially eight new products over the next few years.

Lilly has been saying for the past several years that partnerships will be crucial to its growth strategy—but in general "partnership" for Lilly has always meant in-licensing. It's off-loaded a few products (its propoxyphene (Darvon) product line, to aaiPharma Inc. 's NeoSan Pharmaceuticals Inc. unit [See Deal], and most recently, to Galen

Holdings PLC, fluoxetine hydrochloride (Serafem), its repackaging, for premenstrual dysphoric disorder, of anti-depressant fluoxetine (Prozac) [See Deal].) But Lilly...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing Focus

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By Ed Silverman

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

RESILIENCE Initiative Navigates The World Of Making Medicines Through VR Technology

 
• By Anabel Costa-Ferreira

The process of manufacturing medicines can often be complex, expensive and harmful to the environment. Initiatives like RESILIENCE UK are seeking to simplify this process, utilizing VR technology to create a more sustainable learning environment for both students and companies.

Q&A: Rentschler’s CEO On The CDMO’s Pivot Away From Cell And Gene Therapy And More

 
• By David Wild

Rentschler Biopharma CEO Benedikt von Braunmühl tells In Vivo about the CDMO's strategic decision to exit the cell and gene therapy manufacturing space.

CCRM: Building A Global Regenerative Medicine Ecosystem From Canadian Roots

 
• By David Wild

The Centre for Commercialization of Regenerative Medicine has spent over a decade crafting a cell and gene therapy ecosystem in Canada. Now it is replicating the model abroad.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.